756 research outputs found
Isotropy, shear, symmetry and exact solutions for relativistic fluid spheres
The symmetry method is used to derive solutions of Einstein's equations for
fluid spheres using an isotropic metric and a velocity four vector that is
non-comoving. Initially the Lie, classical approach is used to review and
provide a connecting framework for many comoving and so shear free solutions.
This provides the basis for the derivation of the classical point symmetries
for the more general and mathematicaly less tractable description of Einstein's
equations in the non-comoving frame. Although the range of symmetries is
restrictive, existing and new symmetry solutions with non-zero shear are
derived. The range is then extended using the non-classical direct symmetry
approach of Clarkson and Kruskal and so additional new solutions with non-zero
shear are also presented. The kinematics and pressure, energy density, mass
function of these solutions are determined.Comment: To appear in Classical and Quantum Gravit
Invariant construction of solutions to Einstein's field equations - LRS perfect fluids II
The properties of LRS class II perfect fluid space-times are analyzed using
the description of geometries in terms of the Riemann tensor and a finite
number of its covariant derivatives. In this manner it is straightforward to
obtain the plane and hyperbolic analogues to the spherical symmetric case. For
spherically symmetric static models the set of equations is reduced to the
Tolman-Oppenheimer-Volkoff equation only. Some new non-stationary and
inhomogeneous solutions with shear, expansion, and acceleration of the fluid
are presented. Among these are a class of temporally self-similar solutions
with equation of state given by , and a class of
solutions characterized by . We give an example of geometry
where the Riemann tensor and the Ricci rotation coefficients are not sufficient
to give a complete description of the geometry. Using an extension of the
method, we find the full metric in terms of curvature quantities.Comment: 24 pages, 1 figur
Mycotoxin exposure and human cancer risk : a systematic review of epidemiological studies
In recent years, there has been an increasing interest in investigating the carcinogenicity of mycotoxins in humans. This systematic review aims to provide an overview of data linking exposure to different mycotoxins with human cancer risk. Publications (2019 and earlier) of caseâcontrol or longitudinal cohort studies were identified in PubMed and EMBASE. These articles were then screened by independent reviewers and their quality was assessed according to the NewcastleâOttawa scale. Animal, crossâsectional, and molecular studies satisfied criteria for exclusion. In total, 14 articles were included: 13 caseâcontrol studies and 1 longitudinal cohort study. Included articles focused on associations of mycotoxin exposure with primary liver, breast, and cervical cancer. Overall, a positive association between the consumption of aflatoxinâcontaminated foods and primary liver cancer risk was verified. Two caseâcontrol studies in Africa investigated the relationship between zearalenone and its metabolites and breast cancer risk, though conflicting results were reported. Two caseâcontrol studies investigated the association between hepatocellular carcinoma and fumonisin B1 exposure, but no significant associations were observed. This systematic review incorporates several clear observations of doseâdependent associations between aflatoxins and liver cancer risk, in keeping with IARC Monograph conclusions. Only few human epidemiological studies investigated the associations between mycotoxin exposures and cancer risk. To close this gap, more inâdepth research is needed to unravel evidence for other common mycotoxins, such as deoxynivalenol and ochratoxin A. The link between mycotoxin exposures and cancer risk has mainly been established in experimental studies, and needs to be confirmed in human epidemiological studies to support the evidenceâbased public health strategies
Genotype reconstruction of paternity in European lobsters (Homarus gammarus)
This is the author accepted manuscript. The final version is available on open access from Public Library of Science via the DOI in this recordData Availability: Microsatellite genotypes of 312 individuals (13 spatial samples of 24 individuals), used in the calculation of regional allele frequencies, microsatellite characterisation, and tests of HWE, linkage and null alleles, are available on the Dryad Digital Repository at http://dx.doi.org/10.5061/dryad.v176mDecapod crustaceans exhibit considerable variation in fertilisation strategies, ranging from pervasive single paternity to the near-ubiquitous presence of multiple paternity, and such knowledge of mating systems and behaviour are required for the informed management of commercially-exploited marine fisheries. We used genetic markers to assess the paternity of individual broods in the European lobster, Homarus gammarus, a species for which paternity structure is unknown. Using 13 multiplexed microsatellite loci, three of which are newly described in this study, we genotyped 10 eggs from each of 34 females collected from an Atlantic peninsula in the south-western United Kingdom. Single reconstructed paternal genotypes explained all observed progeny genotypes in each of the 34 egg clutches, and each clutch was fertilised by a different male. Simulations indicated that the probability of detecting multiple paternity was in excess of 95% if secondary sires account for at least a quarter of the brood, and in excess of 99% where additional sire success was approximately equal. Our results show that multiple paternal fertilisations are either absent, unusual, or highly skewed in favour of a single male among H. gammarus in this area. Potential mechanisms upholding single paternal fertilisation are discussed, along with the prospective utility of parentage assignments in evaluations of hatchery stocking and other fishery conservation approaches in light of this finding.European Social FundFisheries Charitable Trust of the Fishmongers' Company, U
The influence of Mn on the tensile properties of SSM-HPDC A1-Cu-Mg-Ag alloy A201
Synopsis: A201 aluminium alloy is a high strength casting alloy with a nominal composition of Al-4.6Cu-0.3Mg-0.6Ag. It is strengthened by the Ω(Al2Cu) phase and the Ξâ(Al2Cu) phase during heat treatment. Further strengthening of this alloy system can be obtained through the addition of transition elements, but care must be taken as other elements might have adverse effects on the mechanical properties. The objective of this study is to determine the influence of Mn on the tensile properties of rheo-processed Al-Cu-Mg-Ag alloy A201.
ThermoCalc software was used to predict the different phases that can be expected in the alloys, and scanning electron microscopy (SEM) with energy dispersive spectroscopy (EDS) was used to investigate the actual phases that formed. The influence of these phases on tensile properties is quantified. SEM and ThermoCalc revealed that there is an increased amount of the Al20Cu2Mn3 with increasing Mn. The tensile properties showed that high amounts of Mn do have adverse effects on the tensile properties of alloy A201, especially the ductility
Genetic homogeneity in the deep-sea grenadier Macrourus berglax across the North Atlantic Ocean
Paucity of data on population structure and connectivity in deep sea species remains a major obstacle to their sustainable management and conservation in the face of ever increasing fisheries pressure and other forms of impacts on deep sea ecosystems. The roughhead grenadier Macrourus berglax presents all the classical characteristics of a deep sea species, such as slow growth and low fecundity, which make them particularly vulnerable to anthropogenic impact, due to their low resilience to change. In this study, the population structure of the roughhead grenadier is investigated throughout its geographic distribution using two sets of molecular markers: a partial sequence of the Control Region of mitochondrial DNA and species-specific microsatellites. No evidence of significant structure was found throughout the North Atlantic, with both sets of molecular markers yielding the same results of overall homogeneity. We posit two non-mutually exclusive scenarios that can explain such outcome: i) substantial high gene flow among locations, possibly maintained by larval stages, ii) very large effective size of post-glacially expanded populations. The results can inform management strategies in this by-caught species, and contribute to the broader issue of biological connectivity in the deep ocean
Whole exome sequencing in patients with Williams-Beuren syndrome followed by disease modeling in mice points to four novel pathways that may modify stenosis risk
Supravalvular aortic stenosis (SVAS) is a narrowing of the aorta caused by elastin (ELN) haploinsufficiency. SVAS severity varies among patients with Williams-Beuren syndrome (WBS), a rare disorder that removes one copy of ELN and 25-27 other genes. Twenty percent of children with WBS require one or more invasive and often risky procedures to correct the defect while 30% have no appreciable stenosis, despite sharing the same basic genetic lesion. There is no known medical therapy. Consequently, identifying genes that modify SVAS offers the potential for novel modifier-based therapeutics. To improve statistical power in our rare-disease cohort (Nâ=â104 exomes), we utilized extreme-phenotype cohorting, functional variant filtration and pathway-based analysis. Gene set enrichment analysis of exome-wide association data identified increased adaptive immune system variant burden among genes associated with SVAS severity. Additional enrichment, using only potentially pathogenic variants known to differ in frequency between the extreme phenotype subsets, identified significant association of SVAS severity with not only immune pathway genes, but also genes involved with the extracellular matrix, G protein-coupled receptor signaling and lipid metabolism using both SKAT-O and RQTest. Complementary studies in Eln+/-; Rag1-/- mice, which lack a functional adaptive immune system, showed improvement in cardiovascular features of ELN insufficiency. Similarly, studies in mixed background Eln+/- mice confirmed that variations in genes that increase elastic fiber deposition also had positive impact on aortic caliber. By using tools to improve statistical power in combination with orthogonal analyses in mice, we detected four main pathways that contribute to SVAS risk
Hypotension due to Kir6.1 gainâofâfunction in vascular smooth muscle
BACKGROUND: K(ATP) channels, assembled from poreâforming (Kir6.1 or Kir6.2) and regulatory (SUR1 or SUR2) subunits, link metabolism to excitability. Loss of Kir6.2 results in hypoglycemia and hyperinsulinemia, whereas loss of Kir6.1 causes Prinzmetal anginaâlike symptoms in mice. Conversely, overactivity of Kir6.2 induces neonatal diabetes in mice and humans, but consequences of Kir6.1 overactivity are unknown. METHODS AND RESULTS: We generated transgenic mice expressing wildâtype (WT), ATPâinsensitive Kir6.1 [Gly343Asp] (GD), and ATPâinsensitive Kir6.1 [Gly343Asp,Gln53Arg] (GDâQR) subunits, under Creârecombinase control. Expression was induced in smooth muscle cells by crossing with smooth muscle myosin heavy chain promoterâdriven tamoxifenâinducible Creârecombinase (SMMHCâCreâER) mice. Three weeks after tamoxifen induction, we assessed blood pressure in anesthetized and conscious animals, as well as contractility of mesenteric artery smooth muscle and K(ATP) currents in isolated mesenteric artery myocytes. Both systolic and diastolic blood pressures were significantly reduced in GD and GDâQR mice but normal in mice expressing the WT transgene and elevated in Kir6.1 knockout mice as well as in mice expressing dominantânegative Kir6.1 [AAA] in smooth muscle. Contractile response of isolated GDâQR mesenteric arteries was blunted relative to WT controls, but nitroprusside relaxation was unaffected. Basal K(ATP) conductance and pinacidilâactivated conductance were elevated in GD but not in WT myocytes. CONCLUSIONS: K(ATP) overactivity in vascular muscle can lead directly to reduced vascular contractility and lower blood pressure. We predict that gain of vascular K(ATP) function in humans would lead to a chronic vasodilatory phenotype, as indeed has recently been demonstrated in Cantu syndrome
Nutritional safety and suitability of a specific protein hydrolysate derived from whey protein concentrate and used in an infant and follow-on formula manufactured from hydrolysed protein by HIPP-Werk Georg Hipp OHG (dossier submitted by meyer.science GmbH)
The European Commission asked EFSA to deliver an opinion on the nutritional safety and suitability of a specific protein hydrolysate. It is derived from whey protein concentrate and used in infant and follow-on formula by HIPP-Werk Georg Hipp OHG. The dossier that was submitted to the European Commission aimed at requesting an amendment of Regulation (EU) 2016/127 with respect to the protein sources that may be used in infant and/or follow-on formula. This opinion does not cover the assessment of the safety of the food enzymes used in the manufacture of the protein hydrolysate. The protein hydrolysate under evaluation is sufficiently characterised with respect to the fraction of the hydrolysed protein. In the pertinent intervention study provided, an infant formula manufactured from the protein hydrolysate with a protein content of 1.9 g/100 kcal and consumed as the sole source of nutrition by infants for 3 months led to growth equivalent to a formula manufactured from intact cowâs milk protein with the same protein content. No experimental data have been provided on the nutritional safety and suitability of this protein source in follow-on formula. However, given that it is consumed with complementary foods and the protein source is considered nutritionally safe and suitable in an infant formula that is the sole source of nutrition of infants, the Panel considers that the protein hydrolysate is also a nutritionally safe and suitable protein source for use in follow-on formula. The Panel concludes that the protein hydrolysate under evaluation is a nutritionally safe and suitable protein source for use in infant and follow-on formula, as long as the formula in which it is used contains a minimum of 1.9 g/100 kcal protein and complies with the compositional criteria of Commission Delegated Regulation (EU) 2016/127 and the amino acid pattern in its Annex IIIA
Nutritional safety and suitability of a specific protein hydrolysate derived from whey protein concentrate and used in an infant and follow-on formula manufactured from hydrolysed protein by Danone Trading ELN B.V
The European Commission asked EFSA to deliver an opinion on the nutritional safety and suitability of a specific protein hydrolysate. It is derived from whey protein concentrate and used in an infant and follow-on formula by Danone Trading ELN B.V, which submitted a dossier to the European Commission to request an amendment of Regulation (EU) 2016/127 with respect to the protein sources that may be used in the manufacture of infant and/or follow-on formula. This opinion does not cover the assessment of the safety of the food enzymes used in the manufacture of the protein hydrolysate. The protein hydrolysate under evaluation is sufficiently characterised with respect to the fraction of the hydrolysed protein. In the pertinent intervention study provided, an infant formula manufactured from the protein hydrolysate with a protein content of 2.3 g/100 kcal and consumed as the sole source of nutrition by infants for 3.5 months led to growth equivalent to a formula manufactured from intact cow's milk protein (2 g protein/100 kcal). No experimental data have been provided on the nutritional safety and suitability of this protein source in follow-on formula. However, given that it is consumed with complementary foods and the protein source is considered nutritionally safe and suitable in an infant formula that is the sole source of nutrition of infants, the Panel considers that the protein hydrolysate is also a nutritionally safe and suitable protein source for use in follow-on formula. The Panel concludes that the protein hydrolysate under evaluation is a nutritionally safe and suitable protein source for use in infant and follow-on formula, as long as the formula in which it is used contains a minimum of 2.3 g/100 kcal protein and complies with the compositional criteria of Commission Delegated Regulation (EU) 2016/127 and the amino acid pattern in its Annex IIIA
- âŠ